医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Todo Works Targets Global Wheelchair Market With Its Special Wheelchair for Children and Wheelchair Power Add-on

2022年05月09日 PM10:00
このエントリーをはてなブックマークに追加


 

SIHEUNG, South Korea

Todo Works Co., Ltd., a Korean startup manufacturing wheelchairs and wheelchair power aids, announced that it will expand into the global wheelchair market with its innovative wheelchair products.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005323/en/

“Why not use an electric wheelchair?” This is the question which was led to the creation of Todo Works. In 2015, Jae-Shin Shim, CEO of Todo Works, met with his daughter’s friend who was in a manual wheelchair. It was the first time that he had looked closely at a wheelchair, as he had not had much contact with the disabled until then. His daughter’s friend informed him that Manual wheelchair is too hard to push by hand, so he can’t move even 100m. So he asked him, “Why not use an electric wheelchair?” He responded, “Electric wheelchairs are large and heavy, so it is too difficult to load it in a car. I use a manual wheelchair when traveling by car.”

At that time, he was running a company that made mock-ups or prototypes, which are test models produced in small quantities to preview performance or appearance when developing or designing a new product. He made a promise that he would attach a device to the wheelchair. Three months later, he finally developed a small device for manual wheelchairs and presented it to his daughter’s friend. That small device changed the child’s entire life. CEO Shim recalled, “I was proud when I heard that the child was able to go to the hospital and travel to nearby places thanks to the device.”

Afterward, the parents of other children with disabilities asked him if they could also purchase the device. CEO Shim said, “I received more than 100 calls a day asking if they could purchase the device.” The following year, Todo Works, a startup specializing in manufacturing ‘Todo-I’, a special seating wheelchair for children, and ‘Todo Drive’, a wheelchair power add-on, was born.

Todo Drive is a groundbreaking product that represents the original ideas of CEO Shim when he developed the device for a child. It is only half the price of competing products. It accomplishes this by lowering the unit price through producing all the parts in-house. Also, it is the lightest product among the world’s wheelchair power add-on devices with an ultra-lightweight of about 5kg as it uses lightweight materials. Its various settings can be changed according to the user’s needs, and the controls couldn’t be easier via a built-in IoT sensor that can be paired to a smartphone. Todo Drive began international sales by signing 45 partnerships with 26 countries, starting with Austria and Australia in 2020.

Todo Works also manufactures a wheelchair referred to Todo-I which is intended for children. This wheelchair is equipped with a power assist device and a steering wheel so that the wheelchair can be moved freely without much effort. Like Todo Drive, the price is reasonable, and the size can be easily adjusted according to the growth stages of the child, so he or she can comfortably use a wheelchair that will adapt to their body until they become an adult. 10 attractive colors to appeal to children are also available.

CEO Shim has expressed his aspirations for the future as follows. “The medical assistive device industry requires innovative technology that goes beyond having a good heart. Todo Works’ goal is to occupy 30% of the global wheelchair power add-on device market and make a barrier-free world where everyone can enjoy the freedom of movement.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005323/en/

CONTACT

Todo Works Co., Ltd.

Cheong Han

+82-80-420-7272

sales@todo-works.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 《新英格兰医学杂志》发表Fazirsiran治疗α-1抗胰蛋白酶缺乏症患者的二期研究结果
  • Twist Bioscience and Ildong Pharmaceutical Enter into a Collaboration to Enhance Antibody Discovery for Applications in Immuno-oncology
  • 沃博联结束战略评估,决定保留表现优异的博姿业务
  • BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
  • Work for Humankind:联想技术为偏远岛屿开启无限可能